PEP005 (ingenol mebutate) Gel, 0.05%
Sponsors
Peplin
Conditions
Actinic KeratosisSuperficial Basal Cell Carcinoma
Phase 2
A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis
CompletedNCT00852137
Start: 2009-03-31End: 2009-06-30Updated: 2015-03-06
PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
CompletedNCT01325688
Start: 2011-04-30End: 2012-03-31Updated: 2016-02-26